Lore Lyndsey Moran
Psychiatric/Mental Health · Lafayette, LANPI 1952805053
Payments from drug & device makers
Across 745 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$948
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$781
- Sunovion Pharmaceuticals Inc.$650
- plus $6K from 26 others
What the payments were for
- Food & beverage$12,26699%
- Education$1651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 134 | $1,766 |
| Teva Pharmaceuticals USA, Inc. | 67 | $1,344 |
| Alkermes, Inc. | 95 | $1,322 |
| Johnson & Johnson(2 entities) | 48 | $948 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $781 |
| Sunovion Pharmaceuticals Inc. | 64 | $650 |
| Braeburn Inc. | 29 | $622 |
| Corium, LLC | 34 | $583 |
| Harmony Biosciences LLC | 14 | $577 |
| Otsuka America Pharmaceutical, Inc. | 25 | $505 |
| Vanda Pharmaceuticals Inc. | 18 | $424 |
| Noven Therapeutics, LLC | 24 | $384 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $374 |
| Neurocrine Biosciences, Inc. | 28 | $363 |
| Tris Pharma Inc | 22 | $350 |
| E.r. Squibb & Sons, L.L.C. | 10 | $206 |
| Axsome Therapeutics, Inc. | 9 | $200 |
| Indivior Inc. | 9 | $189 |
| Supernus Pharmaceuticals, Inc. | 9 | $173 |
| Ironshore Pharmaceuticals Inc. | 7 | $121 |
| Almatica Pharma LLC | 4 | $99 |
| Lundbeck LLC | 4 | $91 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Avanir Pharmaceuticals, Inc. | 3 | $59 |
| Eisai Inc. | 3 | $54 |
| Neos Therapeutics, LP | 2 | $30 |
| Noven Pharmaceuticals, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$401
How this compares
$12,431 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 34 | $105,198 |
| IngrezzaValbenazine Tosylate | 11 | $94,316 |
| LybalviOlanzapine/Samidorphan Malate | 37 | $64,492 |
| VraylarCariprazine Hcl | 21 | $35,391 |
| CaplytaLumateperone Tosylate | 16 | $26,547 |
| Lurasidone Hcl | 53 | $17,694 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $16,312 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,872 |
| BelsomraSuvorexant | 16 | $7,648 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $5,503 |
| Lisdexamfetamine Dimesylate | 15 | $4,059 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 87 | $3,131 |
| Buprenorphine Hcl | 60 | $2,488 |
| Chlorpromazine Hcl | 13 | $1,934 |
| Quetiapine Fumarate | 103 | $1,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $948 | $105,19834 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $363 | $94,31611 claims |
| Alkermes, Inc.Lybalvi | $1,322 | $64,49237 claims |
| AbbVieVraylar | $1,766 | $35,39121 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $781 | $26,54716 claims |
| Axsome Therapeutics, Inc.Auvelity | $200 | $16,31214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $374 | $7,87220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lafayette
- Melissa GuilbeauLafayette$122K
- Bryant DronetteLafayette$17K
- Cinderella BroussardLafayette$14K
- Danielle ThreattsLafayette$11K
- Seth WoodruffLafayette$10K
- Latonya WoodsLafayette$10K
- Laura KightLafayette$9K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.